Recover Investment Losses: Class Action Initiated Against Capricor Therapeutics, Inc. (CAPR)
Levi & Korsinsky announced a securities class action filed against Capricor Therapeutics covering shareholders who purchased CAPR securities between December 17, 2025 and July 29, 2026. The complaint alleges the company changed the pre-specified statistical analysis plan for Deramiocel clinical data without prior FDA agreement before resubmitting the BLA, creating substantial regulatory approval risk for Duchenne muscular dystrophy.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.